Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta,beta-dimethylacrylalkannin, also known as Arnebin 1, is a naturally derived naphthoquinone compound extracted from the roots of several plants, including *Alkanna tinctoria*, *Lithospermum erythrorhizon*, and *Alkanna cappadocica*. It is a small molecule that exhibits a broad spectrum of biological activities, including wound healing, anti-inflammatory, antimicrobial, and antitumor properties. In oncology research, it has been identified as a potent inhibitor of Fibroblast Growth Factor Receptor 1 (FGFR1), binding directly to the ATP-binding pocket to suppress downstream signaling pathways, induce cell cycle arrest, and promote apoptosis in colorectal cancer and hepatocellular carcinoma models. Additionally, the compound has shown inhibitory activity against Protein Tyrosine Phosphatase 1B (PTP1B), suggesting potential therapeutic utility in the treatment of diabetes. While it is widely used as a research chemical and has been incorporated into experimental topical formulations for skin regeneration, it is not currently an approved pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta,beta-dimethylacrylalkannin.